Top 5 Biotechnology Startup Investors in Isle of Man in May 2025
A list of 5 angel investors and VC (Venture Capital) funds that invest in Biotechnology startups based in Isle of man. We rank investors based on the number of investments they made in Biotechnology companies from Isle of man. We update this investor list every month.Top 5 Biotechnology Startup Investors in Isle of Man in May 2025
Investor | Biotechnology Isle of Man investments |
---|---|
Jim Mellon | 1 |
Foresite Capital | 1 |
Juvenescence | 1 |
Greg Bailey | 1 |
Andrew Banks | 1 |
Jim Mellon is an international investor with interests in several industries. After leaving Oxford, where he studied PPE, (Philosophy, Politics and Economics) he worked in Asia and the United States for two fund management companies, GT and Thornton, before establishing his own business in 1991. His business operations include two components, alisted fund management company called Charlemagne Capital, and an Asian mining group, Regent Pacific.In addition, Mr. Mellon is Co-Chairman of West African Minerals Corporation and Regent Pacific Group. He is on the board of a number of public quoted companies, including Brazilian Gold Corporation, Charlemagne Capital Limited, Manx Financial Group, Plethora Solutions, Polo Resources, Port Erin Biophara Investments Limited, and the Speymill plc. He is the life tenant of a trust which owns the Burnbrae Group, which has substantial assets in the biotechnology, financial services, property, mining and leisure sectors. Mr. Mellon spends most of his time working on startup ideas and investing. His book, “Wake Up!” was published in 2005; his second book "10 Investments for the Ten Years Ahead" was published in 2008. In 2012, he co-wrote "Cracking the Code" which focuses on the biotechnology sector and how to profit from it. Mr. Mellon lives in the Isle of Man, Brussels and Ibiza and is an honorary fellow of Oriel College, Oxford.
Show more
Investment focus
- Biotechnology, Food and Beverage, Health Care
- Series A, Seed, Funding Round
- United States, United Kingdom, Germany
Portfolio highlights
- Voxia — Amy collects and analyzes information from all over the web and provides actionable insights about your leads, prospects and clients, all in one click.
- Monaco Foundry — We are a team of Serial Entrepreneurs, former Senior Government Advisors and Fortune 500 Executives. A global venture accelerator that invests in early to mid-stage companies and their growth through a unique sweat equity model.
- The Duppy Share — The Duppy Share Caribbean Rum is the best rum for cocktails, mixed drinks and rum gifts. Try all our rum recipes, from rum and ginger to dark rum punch.
We are a multi-stage investment firm, investing in companies that leverage biology and big data to transform healthcare.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series B, Series C, Series A
- United States, United Kingdom, Australia
Portfolio highlights
- RayThera — RayThera specializes in developing breakthrough small molecule therapies for critical unmet needs in immunology. Backed by decades of drug discovery expertise, we accelerate the development process while maintaining rigorous standards.
- Eikon Therapeutics — Eikon Therapeutics is a drug discovery and development company that leverages super-resolution microscopy as well as the latest advances in biology, chemistry, engineering, and automation toward the goal of discovering and inventing innovative therapies that will improve and extend life.
- Latigo Biotherapeutics — Operator of a drug discovery company intended to develop novel, non-opioid therapies for chronic pain. The company utilizes unique, translated insights to provide a differentiated approach to targeting therapeutics across the blood-nerve barrier, enabling patients to get access to a pain management therapy that does not create addiction, dependenceor tolerability.
We extend healthy lifespan through developing innovative medicines that target core aging mechanisms to not only treat but prevent age-related diseases.
Show more
Investment focus
- Biotechnology, Pharmaceutical, Health Care
- Funding Round, Series A, Debt Financing
- United States, Hong Kong, Isle of Man
Portfolio highlights
- LyGenesis — LyGenesis is an organ regeneration company enabling a patient's own lymph nodes to be used as bioreactors to regrow functioning ectopic organs. Their initial target organ for clinical development is liver regeneration, with a focus on helping patients with end stage liver disease (ESLD).
- MDI Therapeutics — MDI Therapeutics is an operator of a discovery stage company focused on developing novel therapies for fibrotic diseases. The company have developed a proprietary discovery platform which has successfully identified novel small molecule and protein drug candidates, and have advanced these programs through key translational experiments usingclinical biomarkers.
- Souvien Therapeutics — Souvien Therapeutics is a biotechnology company focused on developing therapeutic agents to modulate critical epigenetic mechanisms associated with neurodegeneration.
Dr. Gregory H. Bailey is a Managing Partner at Palantir Group, Inc. Dr. Bailey is the Co-founder of Ascent Healthcare Solutions; VirnetX Inc. (AMEX:VHC) and Duramedic Inc. He was also the initial public financier and an independent director of Medivation, Inc. (NASDAQ:MDVN), from 2005 to December 2012. Dr. Bailey served as the Managing Director andco-Head of Life Sciences at MDB Capital Group LLC from May 2004 to January 2007. Previously he served as Life Sciences Analyst at Participating Capital, Corp. He has served on the board of directors of multiple public companies. Dr. Bailey has Medical Doctorate from the University of Western Ontario and practiced medicine as an emergency physician for ten years.
Show more
Investment focus
- Biotechnology, Pharmaceutical, Medical
- Seed, Series A, Funding Round
- United States, Isle of Man
Portfolio highlights
- Juvenescence — We extend healthy lifespan through developing innovative medicines that target core aging mechanisms to not only treat but prevent age-related diseases.
- Bristol-Myers Squibb — Bristol Myers Squibb is a global biopharmaceutical company committed to discovering, developing and delivering innovative medicines to patients with serious diseases.
- Biohaven Pharmaceutical — Biohaven is a clinical-stage biopharmaceutical company. It has a portfolio of late-stage product candidates targeting neurological diseases, including rare disorders. The company product candidates are based on multiple mechanisms-calcitonin gene-related peptide receptor antagonists, glutamate modulators and myeloperoxidase inhibitor. Its pipelineproducts include BHV3000-301, BHV3000-302, BHV3000-303, and others.
Andrew Banks - Chairman and Co-Founder @ ABRY Partners
Show more
Investment focus
- Biopharma, Biotechnology, Pharmaceutical
- Seed
- Isle of Man
Portfolio highlights
- Juvenescence — We extend healthy lifespan through developing innovative medicines that target core aging mechanisms to not only treat but prevent age-related diseases.
Investors by industry
Impact
Biotech
Gaming
FinTech
Google
Energy
Proptech
Marketplace
Consumer
Hardware
Artificial intelligence
Health Care
Climate
Community
EdTech
Sustainability
Venture Capital
Clean Energy
Real Estate
Financial Services
Video Games
B2B
Education
Publishing
Finance
Food and Beverage
Beauty
Social Media
Medical
Internet
Manufacturing
eSports
Construction
Digital Media
Art
Local
Sports
Music
Enterprise Software
Social Network
Wellness
Email
Franchise
Android
Mobile
Legal
Mobile Advertising
Platforms
Cannabis
Hospitality
Biotechnology
Travel
Fitness
Recruiting
Automotive
Medical Device
Social
Crowdfunding
Wine And Spirits
CleanTech
Transportation
Mobile Apps
InsurTech
Enterprise
Infrastructure
Web3
Photography
LGBT
Retail
Big Data
Organic Food
Payments
Fashion
Oil and Gas
SaaS
Film
Life Science
Theatre
Non Profit
Renewable Energy
Sporting Goods
Restaurants
Social Impact
Celebrity
Software
Cryptocurrency
Agriculture (agtech)
Machine Learning
Media (entertainment)
Facebook
Blockchain
Investors by country
United Kingdom
Germany
India
United States
Ireland
South Korea
Canada
Australia
New Zealand
Middle East
Oceania
Europe
Asia
South Africa
Armenia
Brazil
Qatar
Indonesia
Spain
China
Saudi Arabia
Sri Lanka
Vietnam
Africa
LATAM
Japan
Singapore
Finland
Estonia
Hungary
Ethiopia
Hong Kong
Georgia
Egypt
Ecuador
Denmark
France
Faroe Islands
Ghana
Croatia
Gibraltar
Bulgaria
Chile
Belize
Barbados
Costa Rica
Greece
Belgium
Bahrain
Belarus
Bermuda
Czech Republic
Algeria
Mali
Mexico
Liberia
Israel
Philippines
Malaysia
Italy
Lithuania
Liechtenstein
Kuwait
Norway
Morocco
Myanmar
Lebanon
Mauritius
Peru
Jersey
Panama
Malta
Nicaragua
Sweden
El Salvador
Uruguay
Portugal
Zambia
Dominican Republic
Ukraine
Uzbekistan
Senegal
Azerbaijan
Seychelles
Nigeria
Bahamas
Namibia
Iceland
Venezuela
Iraq
Tajikistan
Taiwan
Serbia
United Arab Emirates
Uganda
Sierra Leone
Turkey
Jamaica
Thailand
Honduras
Tunisia
San Marino
Rwanda
Puerto Rico
Isle of Man
Poland
Bolivia
Russian Federation
Luxembourg
Tanzania
Slovenia
Zimbabwe
Togo
Albania
Pakistan
Grenada
Romania
Jordan
Argentina
Bangladesh
Kenya
Kazakhstan
Cayman Islands
Cambodia
Oman
Cyprus
Latvia
Austria
Cameroon
Switzerland
Colombia
Marshall Islands
Guatemala
Investors in Isle of Man by industry